Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase NA 3Phase 3 3Phase 4 2Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Head & Neck 1CNS 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Tablets × Breast × Clear all
NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Forward Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
196 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡